ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pain"

  • Abstract Number: 1739 • ACR Convergence 2020

    Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption

    Sofia Pazmino1, Annelies Boonen2, Diederik De Cock1, Veerle Stouten1, Delphine Bertrand1, Johan Joly3, Rene Westhovens4 and Patrick Verschueren5, 1KU Leuven, Leuven, Belgium, 2Maastricht University Medical Center, Maastricht, Netherlands, 3University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, 4University Hospitals Leuven, Belgium, Leuven, Belgium, 5University Hospital Leuven, Leuven, Belgium

    Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
  • Abstract Number: 0306 • ACR Convergence 2020

    Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Alexis Ogdie1, Taylor Blachley2, Kelechi Emeanuru2, Sven Richter3, Benoit Guerette3 and Philip Mease4, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Corrona, LLC, Waltham, MA, 3Amgen Inc., Thousand Oaks, 4Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: The efficacy of apremilast vs placebo for the treatment of oligoarticular PsA of ≤2 years duration is being investigated in the FOREMOST trial (NCT03747939).…
  • Abstract Number: 0742 • ACR Convergence 2020

    Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis

    Hollis Krug1, Nicole Blanshan2, Christopher Dorman2 and Sandra Frizelle2, 1Minneapolis VAHCS and University of Minnesota Medical School, Minneapolis, MN, 2Minneapolis VAHCS, Minneapolis

    Background/Purpose: Neurotoxins are increasingly being proposed as analgesics for arthritis pain. Phase II and III clinical trials have shown efficacy but with potential toxicities such…
  • Abstract Number: 1215 • ACR Convergence 2020

    Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

    David Walker1, Tsutomu Takeuchi2, Beatrix Bartok3, Shangbang Rao3, I-Heng Lee4, Robin Besuyen5, Jacques-Eric Gottenberg6 and Mark Genovese3, 1Northumbria Healthcare Trust, North Shields, United Kingdom, 2Keio Univ School of Medicine, Tokyo, Japan, 3Gilead Sciences, Inc., Foster City, CA, 4Gilead Sciences, Foster City, CA, 5Galapagos BV, Leiden, Netherlands, 6Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain…
  • Abstract Number: 1640 • ACR Convergence 2020

    Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies

    Thomas Schnitzer1, Francis Berenbaum2, Philip G Conaghan3, Robert Dworkin4, Takaharu Yamabe5, Isabelle Davignon5, Stefan Wilhelm6, Erika Dragon7 and Lars Viktrup6, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, 4University of Rochester School of Medicine and Dentistry, Rochester, NY, 5Pfizer Inc, Groton, CT, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Ltd, Budapest, Hungary

    Background/Purpose: Tanezumab is under investigation for the treatment of moderate to severe OA pain. As part of the phase 3 OA program, two randomized, placebo-controlled…
  • Abstract Number: 1854 • ACR Convergence 2020

    NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis

    Siba Raychaudhuri1 and Smriti Raychaudhuri2, 1UC Davis, School of Medicine, Davis, CA, 2VA Sacramento Medical Center, Davis, CA

    Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…
  • Abstract Number: 0340 • ACR Convergence 2020

    Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity

    Maria Elisa Acosta1, Olga Compán2, Sonia Pastor1, Guadalupe Manzano Canabal1, Luis Gomez-Lechon Quiros3, Cristina Hidalgo Calleja4, Olga Martinez Gonzalez5, Ana Isabel Turrión1, Javier Del Pino-Montes1 and Carlos Montilla Morales1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, ´Salamanca, Spain, 3Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, 4Hospital Universitario Salamanca, Salamanca, Spain, 5Hospital Universitario de Salamanca, Zamora, Spain

    Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
  • Abstract Number: 0769 • ACR Convergence 2020

    Does the Autoantibody-Response Mature Between Presentation with Arthralgia and Development of Rheumatoid Arthritis? – a Longitudinal Serological Study

    Fenne Wouters1, Ellis Niemantsverdriet1, Nazike Salioska1, Annemarie Dorjée1, René Toes1 and Annette van der Helm - van Mil2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Auto-antibodies in rheumatoid arthritis (RA) are often present years before disease onset but their mere presence does not seem enough to induce RA. Several…
  • Abstract Number: 1218 • ACR Convergence 2020

    Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

    Alan Kivitz1, Yoshiya Tanaka2, Susan Lee3, Lei Ye3, Hao Hu3, Robin Besuyen4 and Bernard Combe5, 1Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 3Gilead Sciences, Inc., Foster City, CA, 4Galapagos BV, Leiden, Netherlands, 5University of Montpellier, Montpellier, France

    Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…
  • Abstract Number: 1641 • ACR Convergence 2020

    Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study

    David Hunter1, Tuhina Neogi2, Melvin Churchill3, Ivan Shirinsky4, Masanari Omata5, Alexander White6, Ali Guermazi2, Robert Fountaine7, Glenn Pixton8, Lars Viktrup9, Mark Brown7, Christine West10 and Kenneth Verburg11, 1Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 2Boston University School of Medicine, Boston, MA, 3Arthritis Center of Nebraska, Lincoln, NE, 4Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, 5Ohimachi Orthopaedic Clinic, Tokyo, Japan, 6Progessive Medical Research, Port Orange, FL, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., Morrisville, NC, 9Eli Lilly and Company, Indianapolis, IN, 10Pfizer Inc, Groton, CT, 11Pfizer Inc, Groton

    Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
  • Abstract Number: 1900 • ACR Convergence 2020

    The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis

    Feyza Nur Yücel1 and Mehmet Tuncay Duruöz2, 1Marmara University School of Medicine PMR Department, Istanbul, Turkey, 2Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey

    Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
  • Abstract Number: 0373 • ACR Convergence 2020

    Medical Cannabis in Ankylosing Spondylitis Following Recreational Legalization: A Prospective Cross-sectional Study

    Emmanouil Rampakakis1, Yoram Shir2, John Sampalis1, Martin Cohen2, Michael Starr2, Winfried Häuser3 and Mary-Ann Fitzcharles2, 1JSS Medical Research, St-Laurent, QC, Canada, 2McGill university, montreal, Canada, 3Technische Universität München, Munich, Germany

    Background/Purpose: Recreational legalization of cannabis has influenced the medical use by patients. When only legal medical access was available in Canada, 4.3% of all rheumatology…
  • Abstract Number: 0811 • ACR Convergence 2020

    Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab

    Janet Pope1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Serge Perrot4, Yvonne Lee5, Anthony Sebba6 and Ernest Choy7, 1Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Paris Descartes University, Paris, Ile-de-France, France, 5Northwestern University Feinberg School of Medicine, Chicago, IL, 6Arthritis Associates, Palm Harbor, Tampa, FL, 7CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
  • Abstract Number: 1224 • ACR Convergence 2020

    Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab

    Esteban Rubio Romero1, Alejandro Muñoz Jiménez2, Rosalia Martinez Perez3 and Lara Mendez Diaz4, 1VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, 2H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 3Virgen del Rocío University Hospital, seville, Spain, 4Virgen del Rocío Hospital, sevilla, Spain

    Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
  • Abstract Number: 1642 • ACR Convergence 2020

    Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study

    Tuhina Neogi1, David Hunter2, Melvin Churchill3, Ivan Shirinsky4, Masanari Omata5, Alexander White6, Ali Guermazi1, Robert Fountaine7, Glenn Pixton8, Lars Viktrup9, Mark Brown7, Christine West10 and Kenneth Verburg11, 1Boston University School of Medicine, Boston, MA, 2Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 3Arthritis Center of Nebraska, Lincoln, NE, 4Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, 5Ohimachi Orthopaedic Clinic, Tokyo, Japan, 6Progessive Medical Research, Port Orange, FL, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., Morrisville, NC, 9Eli Lilly and Company, Indianapolis, IN, 10Pfizer Inc, Groton, CT, 11Pfizer Inc, Groton

    Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology